India Lung Cancer Therapeutics Market Analysis

India Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the India Lung Cancer Therapeutics market will reach a value of $1259 Mn from $542 Mn in 2022, growing at a CAGR of 11.1% during 2022-2030.

India is a lower middle-income, developing country located in Southern Asia bordering the Arabian Sea and the Bay of Bengal. Lung cancer accounts for 5.9 % of all cancers and 8.1 % of cancer-related deaths in India. The prevalence of smoking in lung cancer patients is about 80%. Lung cancer epidemiology in India has progressed from being dominated by histologic types closely related to tobacco smoking (squamous and small cell) to an era in which adenocarcinoma became equally prevalent and has now become the main histologic type. Overall, India's cancer care infrastructure remains inadequate in relation to the population and load of cancer patients. Failure to overcome these shortcomings may result in higher mortality rates and shorter survival rates for cancer patients in India when compared to developed countries.

According to the latest WHO data published in 2020 Lung Cancers Deaths in India reached 88,276 or 1.04% of total deaths. The age-adjusted Death Rate is 7.82 per 100,000 population ranks India 117^th in the world. India's government spends 3 % of its GDP on healthcare.

Market Dynamics

Market Growth Drivers

India is the world's second-largest user and third-largest producer of tobacco. Tobacco products are used by around 28.6 % of the Indian population, accounting for an estimated 267 Mn tobacco users in the country. In India, tobacco consumption has a massive influence on health, particularly cancer. According to the National Cancer Registry Program, tobacco-related malignancies account for 27% of all cancers in both sexes combined. For the treatment of EGFR-mutated advanced or metastatic NSCLC, erlotinib and gefitinib (first generation), afatinib and dacomitinib (second generation), and osimertinib (third generation) are currently approved and available in India. These aspects could boost India's Lung Cancer Therapeutics market.

Market Restraints

The expense of treatment in the private sector is too expensive for low- and middle-income patients. According to WHO standards for a developing country, the required for radiation equipment is 1380, compared to the present 686, which is only enough to serve nearly half of India's population. According to the most recent data from the Atomic Energy Regulatory Board, India has just 514 radiation facilities. There is a significant disparity between the rural and urban sectors in terms of access to radiation facilities and treatment costs. When compared to the public sector, the waiting time in private hospitals is shorter. Despite accounting for one-fifth of the global population, India is represented in only 1.5 % of global clinical trials. Recently, regulatory standards and administrative processes for pharmaceutical clinical trials have been simplified, encouraging big pharmaceutical corporations to bring new medication studies to India. These factors may deter new entrants into the India Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

• Dr. Reddy's Laboratories: Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company that produces several drugs for the treatment of cancer, including lung cancer
• Biocon: Biocon is an Indian biopharmaceutical company that produces several drugs for the treatment of cancer, including lung cancer
• Cipla: Cipla is an Indian multinational pharmaceutical company that produces several drugs for the treatment of cancer, including lung cancer
• Sun Pharmaceutical Industries: Sun Pharmaceutical Industries is an Indian multinational pharmaceutical company that produces several drugs for the treatment of cancer, including lung cancer
• Lupin
• Cadila Healthcare
• Hetero Drugs

Recent Notable Updates

February 2023: The India-Sweden Healthcare Innovation Centre and its expertise partner AstraZeneca India worked with the Directorate of Health Services (DHS) Jammu to include Qure.ai's clever artificial intelligent technology to diagnose lung cancer early on. Qure.ai is expanding the integration of its AI-powered chest x-ray interpretation tool, which can benefit early and easy identification of lung disorders such as lung cancer, under the auspices of the Indo Sweden Healthcare Innovation Centre (ISHIC).

December 2022: Adagrasib, a lung cancer medication developed by Mirati Therapeutics, was recently licenced by the US Food and Drug Administration (FDA). Mirati was seeking FDA approval for the medicine to treat patients with advanced lung cancer who had failed to react to prior treatments. Adagrasib, an oral medication, is intended to target a mutant variant of the KRAS gene, which is found in approximately 13% of Non-Small Cell Lung Cancers (NSCLC), the most common type of the illness, and less commonly in various other solid tumours. Another KRAS inhibitor, Amgen's Lumakras, is already available as a second-line therapy for patients with advanced lung cancer if initial therapy fails or stops responding.

Healthcare Policies and Reimbursement Scenarios

Certain organizations, including the Central Drugs Standard Control Organization (CDSCO), the Ministry of Health and Family Welfare, and the Indian healthcare system, supervise and compensate for lung cancer medicines in India. In India, the CDSCO oversees enforcing and authorizing lung cancer medicines. The Indian healthcare system is the system of reimbursing lung treatment programs approved by the Ministry of Health and Family Welfare. The Indian healthcare system includes medical services and pharmaceuticals for Indian citizens through it a variety of government-funded ventures and insurance programmes. Also, some lung cancer medications may be made available through specific programmes within the Indian healthcare system, such as the National Health Protection Scheme (Ayushman Bharat), which provides capital for lung cancer therapies that are not commonly available.